$6.96
Value $583M
IMMX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$6.96
Value $583M
$270.47
Value $652B
Immix Biopharma (IMMX) has a market value of $583M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, IMMX moved +64.5% and JNJ +36.6%. Dividend yield: IMMX none, JNJ 1.95%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
IMMX$583M
JNJ$652B
JNJ is 1,117 times IMMX
Revenue, 12 months
IMMX–
JNJ$99.3B
Net income, 12 months
IMMX-$46M
JNJ$16.1B
Operating margin
IMMX–
JNJ–
ROIC
IMMX-25.2%
JNJ12.4%
37.6 points apart
P/E
IMMX–
JNJ40.5
Dividend yield
IMMX0.0%
JNJ2.0%
2.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
IMMX+57.8%
JNJ+94.9%
| Period | IMMXWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +64.5%Price +64.5% | +36.6%Price +33.6% |
| 3 years since November 20, 2023 | +57.8%+16.4% a yearPrice +57.8% | +94.9%+24.9% a yearPrice +80.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
IMMXImmix BiopharmaJNJJohnson & Johnson
| Price | $6.96 | $270.47 |
|---|---|---|
| Market value | $583M | $652B |
| Enterprise value (EV) | $247M | $679B |
| P/E | – | 40.5 |
| P/E, 5-year median | – | 21.9 |
| P/B | 1.7 | 8.0 |
| EV/EBIT | – | 38.3 |
| Free cash flow yield | – | 3.2% |
| Revenue, 12 months | – | $99.3B |
|---|---|---|
| Net income, 12 months | -$46M | $16.1B |
| Free cash flow, 12 months | -$45M | $20.6B |
| Earnings per share, 12 months | -$0.83 | $6.59 |
| Revenue growth, year on year | – | 6.1% |
| Revenue growth a year, past | – | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | – | 67.6% |
|---|---|---|
| Operating margin | – | – |
| Net margin | – | 16.2% |
| ROIC | -25.2% | 12.4% |
| ROE | -30.8% | 19.7% |
| Cash | $336M | $17.2B |
|---|---|---|
| Total debt | $965.1K | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($652B) is about 1,117.4 times Immix Biopharma ($583M), at today's prices.
Since November 20, 2023, IMMX's price moved +57.8% and JNJ's +80.4%. With dividends: IMMX +57.8% (+16.4% a year), JNJ +94.9% (+24.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Immix Biopharma and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.